MetaADEDB 2.0 @ LMMD
Lapatinib
(UWYXLGUQQFPJRI-UHFFFAOYSA-N)
Structure
SMILES
Fc1cccc(c1)COc1ccc(cc1Cl)Nc1ncnc2c1cc(cc2)c1ccc(o1)CNCCS(=O)(=O)C.Cc1ccc(cc1)S(=O)(=O)O.Cc1ccc(cc1)S(=O)(=O)O
Molecular Formula:
C43H42ClFN4O10S3
Molecular Weight:
925.461
Log P:
12.3288
Hydrogen Bond Acceptor:
13
Hydrogen Bond Donor:
4
TPSA:
240.23
CAS Number(s):
388082-77-7; 388082-78-8
Synonym(s)
1.
Lapatinib
2.
GW 282974X
3.
GW 572016
4.
GW-282974X
5.
GW-572016
6.
GW282974X
7.
GW572016
8.
Lapatinib Ditosylate
9.
N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
10.
Tykerb
External Link(s)
MeSHD000077341
PubChem Compound139061731
9941095
BindingDB50360454
CHEMBLCHEMBL1201183
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Abdominal PainFAERS: 7US FAERS
2HepatotoxicityFAERS: 6US FAERS
3NauseaFAERS: 6US FAERS
4CardiotoxicityFAERS: 5US FAERS
5Malignant neoplasm progressionFAERS: 5US FAERS
6Alanine Aminotransferase IncreasedFAERS: 4US FAERS
7Disease ProgressionFAERS: 4US FAERS
8Skin toxicityFAERS: 4US FAERS
9jaundiceFAERS: 4US FAERS
10FatigueFAERS: 3US FAERS
11Gastrointestinal toxicityFAERS: 3US FAERS
12NecrosisFAERS: 3US FAERS
13PruritusFAERS: 3US FAERS
14Right ventricular failureFAERS: 3US FAERS
15VomitingFAERS: 3US FAERS
16Angina PectorisFAERS: 2US FAERS
17AstheniaFAERS: 2US FAERS
18Chest PainFAERS: 2US FAERS
19Dry skinFAERS: 2US FAERS
20General physical health deteriorationFAERS: 2US FAERS
21GoutFAERS: 2US FAERS
22HepatitisFAERS: 2US FAERS
23Lymphangiosis carcinomatosaFAERS: 2US FAERS
24MalaiseFAERS: 2US FAERS
25Myocardial InfarctionFAERS: 2US FAERS
26PneumoniaFAERS: 2US FAERS
27PsoriasisFAERS: 2US FAERS
28Pulmonary HypertensionFAERS: 2US FAERS
29Skin reactionFAERS: 2US FAERS
30Transaminases increasedFAERS: 2US FAERS
31Weight decreasedFAERS: 2US FAERS
32Abdominal symptomFAERS: 1US FAERS
33Accidental overdoseFAERS: 1US FAERS
34AcneFAERS: 1US FAERS
35AphagiaFAERS: 1US FAERS
36AphasiaFAERS: 1US FAERS
37Atrial FibrillationFAERS: 1US FAERS
38Blood alkaline phosphatase increasedFAERS: 1US FAERS
39Blood urine presentFAERS: 1US FAERS
40Bronchial ObstructionFAERS: 1US FAERS
41CellulitisFAERS: 1US FAERS
42ColitisFAERS: 1US FAERS
43DizzinessFAERS: 1US FAERS
44Drug therapeutic incompatibilityFAERS: 1US FAERS
45Ejection Fraction DecreasedFAERS: 1US FAERS
46ErythemaFAERS: 1US FAERS
47Eye painFAERS: 1US FAERS
48Febrile NeutropeniaFAERS: 1US FAERS
49Gamma-Glutamyltransferase IncreasedFAERS: 1US FAERS
50GranulomaFAERS: 1US FAERS
51HepatomegalyFAERS: 1US FAERS
52Incorrect dose administeredFAERS: 1US FAERS
53InfarctionFAERS: 1US FAERS
54Multiple sclerosis relapseFAERS: 1US FAERS
55Myocardial StunningFAERS: 1US FAERS
56ObstructionFAERS: 1US FAERS
57PainFAERS: 1US FAERS
58PalpitationsFAERS: 1US FAERS
59Procedural complicationFAERS: 1US FAERS
60Pulmonary arterial hypertensionFAERS: 1US FAERS
61Pulmonary congestionFAERS: 1US FAERS
62Subcutaneous AbscessFAERS: 1US FAERS
63SyncopeFAERS: 1US FAERS
64ThrombosisFAERS: 1US FAERS
65UlcerFAERS: 1US FAERS
66VasculitisFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.